On the basis of the data of genetic status of AML samples (Supplementary Tables 1 and 2), we discovered that p53 protein levels were dramatically reduced in samples with TET2 or WT1 mutations (Figure 2a). This evidence concerns the gene TP53 and acute myeloid leukemia.